Navigation Links
ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
Date:5/19/2008

SAN MARINO, Calif., May 19 /PRNewswire/ -- Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic pancreatic cancer (Chawla et al., ASCO meeting, 2008). Continuing on with the planned dose-escalations of Rexin-G which began in 2005 using lower doses of Rexin-G in a Phase I safety study (Molecular Therapy, 2008), the current Phase I/II study employed higher dose-escalations of Rexin-G given i.v. two to three times a week for 4 weeks, beginning with 8 x 10e11 cfu to 6 x 10e12 cfu with a goal to safely reach the point where the clinical anti-tumor activity of Rexin-G would be clearly and unequivocally demonstrated.

*(LOGO: Send2Press.com/mediaboom/08-0421-Epeius_72dpi.jpg)

The results of this latest Phase I/II study of targeted gene delivery in vivo are very encouraging -- intravenous infusions of Rexin-G demonstrated significant biological activity without toxicity in patients with progressive chemo-resistant pancreatic cancer. Once the overall safety record of repeated infusions of Rexin-G was clearly demonstrated, the FDA approved across the board intra-patient dose-escalations (an adaptive design) to gain better tumor control. These higher doses of Rexin-G were associated with stabilization of disease, using both RECIST and International PET criteria, significant reductions in CA 19.9 levels, and an increase in median overall survival (greater than 6 months) which was twice that observed in the low-dose safety study. No dose-limiting toxicity was observed, even at these higher doses of Rexin-G, thus confirming that repeated infusions of Rexin-G are safe and well-tolerated.

The importance of these progressive dose-escalation studies -- which clearly establish safety before escalating to more potent tumoricidal levels -- is of primary concern in the development of a new genetic medicine like Rexin-G. Moreover, the establishment of a functional dose-response relationship is also of funda
'/>"/>

SOURCE Epeius Biotechnologies
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Commencement 2008: Student innovation could improve data storage, magnetic sensors
2. The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics
3. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
4. The World Economic Forum Announces Technology Pioneers 2008: Mondobiotech Selected
5. Oral PBI-1402 Demonstrates Significant Activity in Chemotherapy-Induced Anemia Phase II Clinical Trial
6. ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study
7. Bringing a New Rhythm to Cardiology Workflow: Siemens Demonstrates Answers to Cardiologys Toughest Questions
8. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
9. USGI Medical Demonstrates First System for Gastrotomy Closure in NOTES
10. Job-related stress: NIST demonstrates fatigue effects in silicon
11. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... The participants committed to not only creating ... own time adjusting, tweaking and testing virtual models and ... for judging. , “I enjoyed being involved as a ... “The entries showed a commendable range exploring the technical ... print medium and the creativity of the contestants.” , ...
(Date:10/1/2014)... 2014 In response to its ... address sales, training and consumer engagement challenges, ... mobile applications to turn their clients’ visions into ... customized mobile app creations, are now featured on ... partnership with Toyota, StudioPMG created a robust cross-platform ...
(Date:10/1/2014)... 30, 2014 Award winning unified ... announces four new-hosted collaboration bundles that combine next ... quality conferencing experiences for low, flat rate fees. ... from, businesses have optimized solutions to meet their ... include audio only minutes (1K, 5K, 10K increments) ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 TeselaGen ... National Science Foundation to expand their bioCAD/CAM software suite, ... and modify DNA. The Small Business Innovation Research Phase ... “j5” technology under exclusive license from the Lawrence Berkeley ... BioEnergy Institute , an LBNL laboratory that develops alternative ...
Breaking Biology Technology:Array Architects Challenges Staff to Create with 3D Printer 2Digital Agency Studio PMG Launches New Case Studies on Website 2SoundConnect Launches New Audio, Web and Video Bundles 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3
... Metformin on Insulin Sensitization Poster Wins One ... ... Seahorse Bioscience, Inc.,leaders in real-time measurement of cellular bioenergetics announced today,the ... award at the 16th European Congress on Obesity (ECO 2008) May ...
... Include Clinical Trial Updates, BETHESDA, Md., July ... OTC Bulletin Board: NWBO), (the,"Company or NWBT"), today ... Chief Executive Officer, will deliver a presentation updating,the ... for the,treatment of cancer, at the "Next Generation ...
... ARGONNE, Ill. (July 17, 2008) Researchers at the U.S. ... industrial partners have won two R&D 100 Awards for ... scientists have been awarded 101 R&D 100 Awards since ... a prestigious R&D 100 Award -- dubbed the "Oscars ...
Cached Biology Technology:Seahorse Bioscience Receives Poster Award from the European Association for the Study of Obesity 2Northwest Biotherapeutics to Present at Next Generation Vaccine Conference 2Argonne researchers win 2 R&D 100 Awards 2Argonne researchers win 2 R&D 100 Awards 3Argonne researchers win 2 R&D 100 Awards 4
(Date:9/30/2014)... Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich report that ... cells more sensitive to chemotherapeutic drugs. They have ... a new target for anti-tumor agents. , ... Professor Stephan Sieber of the Technische Universitt Mnchen ... a potential new weapon in the fight against ...
(Date:9/30/2014)... 30, 2014  Spectra Automation, a trusted ... biotech and power generation industries, announced today ... Manager, an easy-to-use and cost-effective data collection, ... development laboratories. Most upstream ... analyzer systems. Accessing and consolidating data from ...
(Date:9/29/2014)... Clostridium ramosum , coupled with a high-fat diet, may cause ... in mBio , the online open-access journal of the ... the German Institute of Human Nutrition Potsdam-Rehbruecke in Nuthetal observed ... gained weight when fed a high-fat diet. Mice that ... even when consuming a high-fat diet, and mice that had ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2Gut bacteria promote obesity in mice 2
... Leadership Strengthened with Clinical ... Standards-Based Data Management, WHIPPANY, N.J. and ATLANTA, ... it agreed to terms to acquire Zurich,Biostatistics, Inc. ... regulatory submissions, the acquisition further strengthens,ISI,s Clinical Data ...
... SHORES, Calif., Sept. 10 ,Communication Intelligence Corporation (OTC ... signature solutions for business process,automation in the financial ... announced today the appointment of Michael Betts to,the ... over 30 years of experience in the insurance ...
... J. Michael McConnell, Director of,National Intelligence and ... Intelligence will provide valuable insights into the intelligence,challenges ... the United States,Intelligence Community 100 Day Plan for ... The Office of the Director of National Intelligence ...
Cached Biology News:Image Solutions, Inc. Acquires Zurich Biostatistics, Inc. 2Image Solutions, Inc. Acquires Zurich Biostatistics, Inc. 3Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors 2Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors 3